REGISTER
DOWNLOAD AGENDA
Blood Cancer accounts for 10% of new cancer cases diagnosed in the US in 2017. Approximately every 3 minutes one person is diagnosed and every 9 minutes one person dies.
Blood cancer R&D is experiencing rapid growth, representing an enormous opportunity for drug developers, driven by Innovative Cancer Treatment Therapies
The global market for Blood cancer therapeutics, valued at $24 billion in 2015, is poised to reach $38 billion by 2020, expanding by a CAGR of 9.7%
Do You Have the Latest Insights to Transform the Success of Your Pipeline?
Precision: Blood Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
HIGHLIGHTS
CAR-TCR
CHECKPOINT INHIBITORS
ANTIBODY CONSTRUCTS
BIOMARKERS
COMPANION DIAGNOSTICS
34%
26%
12%
12%
9%
7%
Large Drug Developers
Small & Mid-Sized Developers
Academia
& Hospitals
CROs &
Platform Technology
Equipment
Providers
Other
COMPANY TYPE
%
JOB TITLE
%
VP, Director, Head
C-Level
Scientists
Managers
48%
23%
18%
11%
GOALS OF THE EVENT
Learning Objectives
Target Audience
JERRY ZELDIS
CMO
Sorrento Therapeutics
HANS-PETER GERBER
CSO and SVP
3T Biosciences
JONATHAN PACHTER
CSO
Verastem
CYRIL KONTO
Exec. Dir. Clinical Development
Allogene
JAGATH R. JUNUTULA
VP
Cellerant Therapeutics
KYLE MACBETH
Senior Director,
Translational Development & Dx
Celgene
DEVON J. SHEDLOCK
VP, Preclinical Development
Poseida Therapeutics
SELDA SAMAKOGLU
Director, Translational Medicine
Bristol-Myers Squibb
RONALD CHEUNG
Director, Clinical Development
Jazz Pharmaceuticals
PIETRO TAVERNA
Exec. Director, Translational medicine.
Sunesis Pharmaceuticals
TAE HAN
VP, Clinical Pharmacology & Translational Medicine
Amphivena Therapeutics
YANG PAN
Director, Biomarker Sciences
Gilead Sciences
VIEW AGENDA
DOWNLOAD PDF
INDUSTRY DELEGATE
Standard rate: $2199
Pharma & Biotech Drug Developers / Solution Providers.
Access to 2-day Conference & Networking Sessions
$2199
(Limited Availability)
BUY NOW
ACADEMIC DELEGATE
Standard rate: $799
Reserved for Non-Profit Organizations.
Access to 2-day Conference & Networking Sessions
$799
(Limited Availability)
BUY NOW
Crowne Plaza San Francisco Airport
1177 Airport Blvd, Burlingame, CA 94010, USA
NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN
contact@neo-synth.com
(+1) 617.500.5172
Your details will not be shared with a third party
Copyright © 2018 | All content produced by: Neo-Synth Ltd.
SEP 18-19 2018
San Francisco, USA
An exclusive, annual biopharma summit providing insights into the research and development of cutting edge treatments for Blood Cancer and a networking forum for precision medicine leaders in this space.
Precision: Blood Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
HIGHLIGHTS
CAR-TCR
IMMUNOTHERAPY
NOVEL APPROACHES
BIOMARKERS
COMPANION DIAGNOSTICS
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
JERRY ZELDIS
CMO
Sorrento Therapeutics
CYRIL KONTO
Exec. Dir. Clinical Development
Allogene
INDUSTRY DELEGATE
Rate Expires on 24 August 2018
Standard Rate of $2199 to Apply Thereafter
Register Now to Save
$1899
(Save $300)
BUY NOW
ACADEMIC DELEGATE
Rate Expires on 24 August 2018
Standard Rate of $799 to Apply Thereafter
Reserved for Non-Profit Organizations. Register Now to Save
$599
(Save $300)
BUY NOW
Crowne Plaza San Francisco Airport
1177 Airport Blvd, Burlingame, CA 94010, USA
DOWNLOAD GUIDE